UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003750
Receipt number R000004535
Scientific Title The safety evaluation of endoscopic biopsy against patients receiving anticoagulatns and antiplatelet agents.
Date of disclosure of the study information 2010/06/16
Last modified on 2012/06/14 09:05:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The safety evaluation of endoscopic biopsy against patients receiving anticoagulatns and antiplatelet agents.

Acronym

The safety evaluation of endoscopic biopsy during antithrombotic therapy.

Scientific Title

The safety evaluation of endoscopic biopsy against patients receiving anticoagulatns and antiplatelet agents.

Scientific Title:Acronym

The safety evaluation of endoscopic biopsy during antithrombotic therapy.

Region

Japan


Condition

Condition

Outpatients undergoing gastrointestinal endoscopy during antithrombotic therapy

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study is aimed to evaluate safety of endoscopic biopsy in gastrointestinal tract for patients receiving anticoagulatns and antiplatelet agents without cessation.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Gastrointestinal bleeding during two weeks after biopsy.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Maneuver

Interventions/Control_1

Endoscopic biopsy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(A)Medical need of gastrointestinal endoscopy.
(B)Comorbidity requiring antithrombotic therapy.
(C)Receiving anticoagulants and/or antiplatelet agents.
(D)Informed consent.
(E)Performance status(ECOG):0-2.
(F)Scheduled blood test about two weeks after biopsy.
(G)Outpatient.

Key exclusion criteria

(A)Strong possibility of lesions requiring more invasive procedures than biopsy.
(B)During hospitalization.
(C)Other severe comorbidities.
(D)During anticancer chemotherapy.
(E)Severe hematological, hepatological, or renal disorder accompanied with hemorrhagic tendency.
(F)INR exceeding the upper limit shown in the guideline by Japanese circulation society.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mitsuhiro Fujishiro

Organization

Graduate School of Medicine, The University of Tokyo.

Division name

Department of Endoscopy and Endoscopic Surgery.

Zip code


Address

7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan.

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Satoshi Ono

Organization

Graduate School of Medicine, The University of Tokyo.

Division name

Department of Gastroenterology.

Zip code


Address


TEL


Homepage URL


Email

satoshi-tky@umin.ac.jp


Sponsor or person

Institute

Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo.

Institute

Department

Personal name



Funding Source

Organization

Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 06 Month 16 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/22350697

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 03 Month 18 Day

Date of IRB


Anticipated trial start date

2010 Year 06 Month 01 Day

Last follow-up date

2012 Year 03 Month 01 Day

Date of closure to data entry

2012 Year 03 Month 01 Day

Date trial data considered complete

2012 Year 03 Month 01 Day

Date analysis concluded

2012 Year 03 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 06 Month 14 Day

Last modified on

2012 Year 06 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004535


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name